ABSTRACT Objective To describe the use of subconjuctival administration of the anti-tumor necrosis factor agent adalimumab for treatment of dry eye in patients with Sjögren’s syndrome, and to invest

NIAID Data Ecosystem30

A Phase II, Multicenter, Randomized, Single-Masked, Sham Injection-Controlled Exposure-Response Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Patients With Geographic Atrophy

眼科临床试验

年龄相关性黄斑变性

This multicenter, randomized, single-masked, sham injection-controlled study will investigate the exposure-response and safety of lampalizumab administered intravitreally every 2 weeks (Q2W) or ever

DataCite Commons2025-05-01 更新20

Reference standard RCTs identified and RCTS identified by author as controlled trial by year of presentation at ARVO.

眼科临床试验

临床试验注册

*Box checked “Yes” for “human clinical trial” (n = 634).†Box checked “Yes” for “human controlled clinical trial” (n = 941).‡Information recorded in trial registration box (n = 797).§Does not include 5

Figshare2015-12-02 更新50

The demographic and clinical characteristics of subjects.

临床生物标志物对比

疾病诊断标准

Data shown are median (range) of each group of subjects. WBC: White blood cell; CEA: Carcino-embryonic antigen; LDH: Lactate dehydrogenase; ADA: Adenosine aminhydrolase. *p<0.05 vs. the HC.

NIAID Data Ecosystem30

SWAN trial: Key ocular eligibility criteria for the study eye.

资源简介：

相关数据集